

# Clinical Trials of Parkinson's Disease Drug Therapies

## Change in Completion Date Dashboard: Q4 2022

posted on ClinicalTrials.gov between Oct. 1, 2022 and Dec. 31, 2022

ClinicalTrials.gov identifier (NCT)	Agent	Company / Sponsor	Agent description	Phase	Trial Title	Enrollment	Prior Primary Completion Date	New Primary Completion Date	Change (Days)
NCT02579473	SER-214 (Rotigotine polymer conjugate)	Serina Therapeutics	Continuous delivery of rotigotine	Phase 1	A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER 214	20	31-Dec-2020	31-Dec-2022	730
NCT03652870	Nortriptyline/Escitalopram	University College London	Antidepressants	Phase 3	Antidepressants Trial in Parkinson's Disease	408	1-Feb-2022	31-Jan-2023	364
NCT03790670	Leukine (sargramostim)	Nebraska University	Recombinant GM-CSF	Phase 1	Biomarker Assessments of Leukine During Treatment of Parkinson's Disease	7	30-Sep-2022	30-Oct-2023	395
NCT04251585	Nasal insulin	HealthPartners Institute	Intra-nasal insulin	Phase 2	Intranasal Insulin in Parkinson's Disease	30	1-Dec-2022	1-Jun-2023	182
NCT04273932	Lithium	Buffalo University	Protein kinase C inhibitor (treatment for bipolar disorder)	Phase 1	Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.	19	1-Jul-2022	1-Dec-2022	153
NCT04332276	DIVE	Lille University Hospital/InBrain Pharma	Intra-cerebroventricular dopamine	Phase 1 Phase 2	Dopaminergic restoration by intraVentriculaire Administration	20	1-Mar-2023	1-Sep-2023	184
NCT04334317	TAK-071	Takeda	M1 positive allosteric modulator	Phase 2	A Study of TAK-071 in People With Parkinson Disease	64	30-Nov-2022	10-Feb-2023	72
NCT04643327	Levetiracetam	Queensland University	Anti-epileptic	Phase 2	Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease	28	1-Jan-2023	1-Jun-2023	151
NCT04651153	UCB7853	UCB and Neuropore	aSN antibody	Phase 1	A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD)	64	1-Sep-2023	24-Nov-2023	84
NCT04739423	CST-103 and CST 107	CuraSen Therapeutics	Restores brain homeostasis	Phase 2	A Study of CST-103 Co-administered With CST-107 in Subjects With Neurodegenerative Disorders	41	1-Jul-2022	4-Jul-2022	3

NCT04750226	Foslevodopa/foscarbidopa (ABBV-951)	Abbvie	Sub-cutaneous L DOPA/Carbidopa prodrug	Phase 3	Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease	130	12-Oct-2024	16-May-2025	216
NCT04777331	Prasinezumab (RO7046015/PRX002)	Roche/Prothena	Immunotherapy (Mab to aSN)	Phase 2	A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease	575	12-Jun-2024	10-Jul-2024	28
NCT04831281	ATH-1017	Athira Pharma	Enhances Hepatocyte Growth Factor activity	Phase 2	ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)	28	1-Oct-2023	1-Apr-2023	-183
NCT05083260	NE3107	Biovie	Reduces neuroinflammation and insulin resistance	Phase 1 Phase 2	NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa	40	15-Nov-2022	21-Nov-2022	6
NCT05104463	CST-103 and CST 107	CuraSen Therapeutics	Restores brain homeostasis	Phase 2	A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease	60	1-Nov-2022	1-Jun-2023	212
NCT05543252	UCB0599	UCB and Neuropore (NPT 200-11)	Inhibitor of aSN misfolding	Phase 2	An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of UCB0599 in Study Participants With Parkinson's Disease	270	1-Dec-2027	28-Dec-2027	27